Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Periggo

    - PMLiVE

    FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

    Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Sandoz separates from Novartis as an independent spin-off company

    The split allows Sandoz to strengthen its position in generics and biosimilars

    - PMLiVE

    Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

    Nearly 500,000 died from an opioid overdose between 1999 and 2019

    - PMLiVE

    Sandoz launches generic oncology treatment in Europe

    Lenalidomide can be used to treat patients with haemato-onocology conditions, following recommendations from recent European Society for Medical Oncology (ESMO) guidelines

    - PMLiVE

    Teva reaches $925,000 settlement to resolve drug price-fixing claims

    Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe

    - PMLiVE

    Pfizer, Sanofi and others set to increase US drug prices in 2021

    Pressure from COVID-19 restrictions leads to drug price increases

    - PMLiVE

    Pfizer, Mylan move ahead with generics merger and spin-out

    The merger had faced a set-back as a result of COVID-19 disruption

    - PMLiVE

    US charges Teva for generic drug price-fixing plot

    Company maintains it has not committed any wrongdoing

    - PMLiVE

    COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

    Fallout from pandemic continues to affect business in myriad ways

    - PMLiVE

    Teva’s weak pipeline hit by Tourette’s drug trial failure

    Drug wasn't able to improve on placebo

    - PMLiVE

    Biogen triumphs over Mylan’s Tecfidera patent challenge

    Shares in Biogen skyrocketed by 32% following ruling

    - PMLiVE

    FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

    Sets stage for lower-cost competition to big-selling drug

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links